PF-07836395 Influenza saRNA for Flu

"This clinical trial is seeking 468 individuals between 18 and 49 years old who have been infected with the influenza virus. In order to be eligible, male candidates must agree to use contraception if they are able of fathering children, while female applicants must not possess child-bearing capabilities; all participants should demonstrate their willingness and ability to adhere to the scheduled visits, treatments plans, laboratory tests etc. Furthermore, volunteers need to be certified as healthy by a medical history review and physical examination (if necessary). Lastly, consent forms will need to be signed in order for an individual's eligibility status to be confirmed."

"The trial, which was first announced on the 28th of April 2022, is in its recruiting phase. The most recent update to this study came through on October 24th 2022 according to clinicaltrials.gov."

"This medical experiment necessitates 468 qualified participants to partake, who are able to do so from either Pinnacle Health Care Center in Pembroke Pines or The Pain Center of Arizona in Phoenix."

"Adhering to the trial's inclusion regulations, only those aged 18-49 are eligible for enrollment."

"The current clinical trial is recruiting patients from a wide array of medical centres, including Pinnacle Health Care Center in Pembroke Pines, Florida; The Pain Center of Arizona in Phoenix, Arizona; and the prestigious Pines Care Research Centre LLC based out of Syracuse, New york. A full list of 25 other eligible locations can be found online."

"As per the study's sponsor, Pfizer, Percentage of participants experiencing systemic events within a 7 day post-vaccination period is the primary observation metric. Secondary metrics include Geometric mean titers (GMTs) analysis at central laboratories for hemagglutination inhibition (HAI), plus Proportion of patients achieving HAI seroconversion and those with an antibody titer exceeding 1:40 as again assessed by a centralized laboratory."

"As this is a Phase 1 trial, with limited data in regards to safety and efficacy, the Power team has assigned PF-07836395 Influenza saRNA a score of one on our scale."